IE 11 is a very old Browser and it`s not supported on this site
Financial Report Consolidated interim financial statements

Consolidated balance sheet

in CHF 1 000

 

Notes

 

31.03.2022

 

31.12.2021

Current assets

 

 

 

 

 

 

Cash and cash equivalents

 

 

 

1 635

 

2 835

Securities

 

4

 

3 118 719

 

3 641 112

Other assets

 

 

 

160

 

135

 

 

 

 

3 120 514

 

3 644 082

Total assets

 

 

 

3 120 514

 

3 644 082

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Short-term borrowings from banks

 

5

 

355 000

 

355 000

Other short-term liabilities

 

 

 

4 458

 

5 431

Tax liabilities

 

 

 

178

 

158

 

 

 

 

359 636

 

360 589

Total liabilities

 

 

 

359 636

 

360 589

 

 

 

 

 

 

 

Shareholders' equity

 

 

 

 

 

 

Share capital

 

6

 

11 080

 

11 080

Treasury shares

 

6

 

(19 716)

 

(9 205)

Retained earnings

 

 

 

2 769 514

 

3 281 618

 

 

 

 

2 760 878

 

3 283 493

Total liabilities and shareholders' equity

 

 

 

3 120 514

 

3 644 082

 

 

 

 

 

 

 

Net asset value per share in CHF

 

 

 

50.10

 

59.40

The notes are an integral part of the condensed consolidated interim financial statements.

The condensed consolidated interim financial statements were approved by the Board of Directors of BB Biotech AG on April 19, 2022.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer